NICE has published four new Technology Appraisals (TAs):
- TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
- TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
- TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
- TA644: Entrectinib for treating NTRK fusion-positive solid tumours.
TA641 provides evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin, and prednisone for untreated systemic anaplastic large cell lymphoma in adults. TA642 offers evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults.
TA643 provides evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors, while TA644 provides evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.
The TAs describe the indications in which these pharmacological therapies are to be used and detail any managed access agreements for their availability.